Analyst firms · Leerink Partners · IONS

Leerink Partners IONS price target and rating history

Ionis Pharmaceuticals Inc. (IONS) · Health Care

Leerink Partners rates Ionis Pharmaceuticals Inc. (IONS) Outperform with a $62 price target, as of its latest action on Jul 24, 2024. It has published 6 rating actions on IONS since August 2021, including 1 upgrade and 0 downgrades. Across 6 firms with a IONS price target in the last 12 months, the median target is $99.50.

Current rating
Outperform
Price target
$62
Median target, all firms
$99.50
Actions on IONS
6

Leerink Partners price target on IONS

$62$46$2920222023202420252026
Leerink Partners price target on IONS, each point a stated target, August 2021 to July 2024.

Every Leerink Partners rating on IONS

How other firms rate IONS

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
BMO Capital MarketsOutperform$66Oct 22, 2026
UBSBuy$88Oct 15, 2026
Wolfe ResearchPeer PerformJul 16, 2026
CitigroupBuy$115May 19, 2026
Canaccord GenuityBuy$110Apr 21, 2026
Raymond JamesOutperform$104Apr 10, 2026
BarclaysOverweight$95Jan 28, 2026

Questions about Leerink Partners and IONS

What is Leerink Partners's price target for IONS?
Leerink Partners's latest stated price target for Ionis Pharmaceuticals Inc. (IONS) is $62, from its action on Jul 24, 2024.
What is Leerink Partners's rating on IONS?
Leerink Partners rates IONS Outperform, a bullish rating, as of Jul 24, 2024.
When did Leerink Partners last change its view on IONS?
On Jul 24, 2024, Leerink Partners upgrades to Outperform from Market Perform, price target $53 to $62.
How does Leerink Partners's IONS target compare with other analysts?
Across 6 firms with a IONS price target in the last 12 months, the median target is $99.50.

More IONS rating histories

All Leerink Partners ratingsIONS news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.